Edaravone Injection Suppliers & Bulk Manufacturers
Available Forms: Injectable Solution
Available Strengths: 30 mg/10 ml
Reference Brands: Radicava(US)
Category:
Orphan Drugs
Edaravone is a free radical scavenger that reduces oxidative stress in neurons, protecting against nerve cell damage. It slows ALS progression, improves muscle strength, and prolongs survival. Benefits include neuroprotection, symptom stabilization, and improved quality of life for ALS patients by supporting neuronal health.
Edaravone injection is available in Injectable Solution
and strengths such as 30 mg/10 ml.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Edaravone injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Edaravone injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Edaravone injection, marketed as Radicava, is approved in the US by the FDA and in the EU via EMA for amyotrophic lateral sclerosis (ALS). Regulatory approval requires comprehensive dossiers including clinical efficacy, safety profiles, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial and quality data for timely approval, while the EMA ensures regional safety and manufacturing compliance. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Supporting regional adherence supports quick approval, safe administration, and global availability, helping ALS patients worldwide by slowing disease progression and improving quality of life through neuroprotective mechanisms.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing